Cervical cancer: From Hippocrates through Rigoni-Stern to zur Hausen

Vaccine

Volumn 27, Issue SUPPL. 1, 2009, Pages A4-

  Gasparini, R ^a   Panatto, D ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

CANCER IMMUNIZATION; CANCER PREVENTION; CLINICAL TRIAL; COLPOSCOPY; EDITORIAL; HEALTH PROGRAM; HUMAN; PRIORITY JOURNAL; UTERINE CERVIX CANCER; VIRUS CARCINOGENESIS; VIRUS STRAIN; WART VIRUS;

EID: 65749088315     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.11.069     Document Type: Editorial

References (30)

1. Dürst M., Gissmann L., Ikenberg H., and zur Hausen H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci USA 80 (1983) 3812-3815
2. Schwarz E., Freese U.K., Gissmann L., Mayer W., Roggenbuck B., Stremlau A., et al. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature 314 (1985) 111-114
3. Institut Jules Bordet. The history of cancer. Available at http://www.bordet.be/en/presentation/history/cancer-e/cancer2.htm [last accessed: September 2008].
4. Griffiths M. Nuns, virgins, and spinsters. Rigoni-Stern and cervical cancer revisited. Br J Obstet Gynaecol 98 (1991) 797-802
5. Scirus for scientific information only. Available at http://www.scirus.com/ [last accessed: September 2008].
6. Rigoni-Stern D.A. Fatti statistici relativi alle malattie cancerose. Giornale per servire ai progressi della Patologia e della Terapia 2 (1842) 507-517
7. Mak R., Van Renterghem L., and Cuvelier C. Cervical smears and human papillomavirus typing in sex workers. Sex Transm Infect 80 (2004) 118-120
8. Bayo S., Bosch F.X., de Sanjosé S., Muñoz N., Combita A.L., Coursaget P., et al. Risk factors of invasive cervical cancer in Mali. Int J Epidemiol 31 (2002) 202-209
9. Menczer J. The low incidence of cervical cancer in Jewish women: has the puzzle finally been solved?. Isr Med Assoc J 5 (2003) 120-123
10. Papanicolaou G.N., and Traut H.F. The diagnostic value of vaginal smears in carcinoma of the uterus. Am J Obstet Gynecol 42 (1941) 193-198
11. Ayre J.E. Selective cytology smear for diagnosis of cancer. Am J Obstet Gynecol 53 (1947) 609-617
12. Ismail S.M., Colclough A.B., Dinnen J.S., Eakins D., Evans D.M., Gradwell E., et al. Observer variation in histopathological diagnosis and grading of cervical intraepithelial neoplasia. BMJ 298 (1989) 707-710
13. zur Hausen H. Condylomata acuminata and human genital cancer. Cancer Res 36 (1976) 794
14. Perkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 75-108
15. Parkin D.M., and Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine 24 Suppl. 3 (2006) S11-S25
16. AIRT working group. I tumori in Italia-Rapporto 2006. Incidenza, mortalità e stime. Epidemiologia e prevenzione 2006. Available at http://www.registri-tumori.it/cms/?q=Rapp2006 [last accessed: August 2008].
17. Ronco G., Ghisetti V., Segnan N., Snijders J.F.P., Gillio-Tos A., Meijer C.J., et al. Prevalence of human papillomavirus infection in women in Turin, Italy. Eur J Cancer 41 2 (2005) 297-305
18. ®). Ther Clin Risk Manag 4 (2008) 65-70
19. Gall S.A. Substantial impact on precancerous lesions and HPV infections through 5.5 years in women vaccinated with the HPV-16/18 L1 VLP AS04 candidate vaccine. AACR annual meeting. Los Angeles, CA (2007)
20. Advisory Committee on Immunization Practices (ACIP). Quadrivalent human papillomavirus vaccine. MMWR 56 (2007) 1-24
21. National Advisory Committee on Immunization (NACI). Statement on human papillomavirus vaccine. CCDR 33 (2007) 1-32
22. Australian Government Department of Health and Ageing: Preventing Cervical Cancer. Available at http://www.health.gov.au/cervicalcancer [last accessed: September 2008].
23. European Centre for Disease Control. ECDC guidance for the introduction of HPV vaccines in EU countries (2008), European Centre for Disease Control, Stockholm
24. King L.A., Lévy-Bruhl D., O'Flanagan D., Bacci S., Lopalco P.L., Kudjawu Y., et al. Introduction of human papillomavirus (HPV) vaccination into national immunisation schedules in Europe: results of the VENICE 2007 survey. Euro Surveill 13 33 (2008) pii=18954
25. Withe C. Scotland starts HPV vaccination programme. BMJ 337 (2008) 543
26. Jit M., Choi Y.H., and Edmunds W.J. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 337 (2008) 769
27. Conferenza Stato-Regioni. Agreement between the central Government, Regions and Autonomous Provinces of Trento and Bolzano regarding the strategy for the active offer of the vaccine against HPV infection in Italy [in Italian]. Available at: http://www.statoregioni.it/Documenti/DOC_016696_264csr.pdf [last accessed: July 2008].
28. Signorelli C., and Colzani E. Age at first intercourse and HPV immunization. J Prev Med Hyg 48 (2007) 37-38
29. Gasparini R., Amicizia D., Manfredi P., Ansaldi F., Lucioni C., Gallelli G., et al. Human papillomavirus vaccination: what is the best choice? A comparison of 16 strategies by means of a decisional model. Epidemiol Infect 17 (2008) 1-9
30. Disease Control Priorities Project. Controlling cancer in developing countries. prevention and treatment strategies merit further study. Available at http://www.dcp2.org [last accessed: September 2008].